Abstract Number: 2156 • ACR Convergence 2024
Differential Item Functioning of Inflammatory Back Pain Criteria in US Subpopulations
Background/Purpose: IInflammatory back pain (IBP) has clinical features that distinguish it from other back pain etiologies. While there are established IBP criteria, in different subpopulations…Abstract Number: 2368 • ACR Convergence 2024
Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Improvements in Pain and Fatigue: Up to 2-Year Results from Two Phase 3 Studies
Background/Purpose: PsA significantly impacts patients' quality of life due to functional limitations, pain, and fatigue.1 Sustained relief from pain and fatigue are therefore important aims…Abstract Number: 0301 • ACR Convergence 2024
Path to Diagnosis in Familial Mediterranean Fever (FMF)
Background/Purpose: Familial Mediterranean Fever (FMF) is a genetic disorder characterized by recurrent febrile episodes and inflammation, most commonly presenting with peritonitis, pleuritis, and arthritis. The…Abstract Number: 0583 • ACR Convergence 2024
Impact of Prior Tumor Necrosis Factor Inhibitor Treatment and Baseline Psoriatic Arthritis Disease Activity on Minimal Clinically Important Improvement Thresholds for Efficacy Outcomes: Post Hoc Analysis of Three Phase 3 Studies of Guselkumab in Patients with Active Psoriatic Arthritis
Background/Purpose: PsA disease activity (DA) and impact on patients (pts) are measured with clinical and pt-reported outcomes1. Minimal clinically important improvement (MCII), the smallest improvement…Abstract Number: 0792 • ACR Convergence 2024
Radiographic and Pain Outcomes from a Phase 3 Trial (OA-07) Evaluating the Efficacy and Safety of Repeat Lorecivivint Injections over 3 Years in Subjects with Knee OA
Background/Purpose: Knee OA has unmet need for safe and efficacious symptom and disease-modifying treatments. Lorecivivint (LOR), an intra-articular (IA) CLK/DYRK inhibitor thought to modulate inflammatory…Abstract Number: 1244 • ACR Convergence 2024
Creation of a New Patient-reported Outcome for a Combined Response Index for Limited Cutaneous SSc Using the FDA Guidance on Patient Reported Outcome Measures: The CRISTAL PRO
Background/Purpose: Limited cutaneous systemic sclerosis (lcSSc) is the most frequent subset of scleroderma, yet there is a paucity of outcome measures to assess symptoms that…Abstract Number: 1335 • ACR Convergence 2024
The Association of Patient-Reported Non-Articular Pain with Musculoskeletal Pain Diagnoses and RA Disease Activity in a Prospective Real-World Cohort of Patients with Early RA
Background/Purpose: Non-articular pain (NAP) is often reported by early RA (eRA) patients, impacts RA remission (REM) but remains poorly defined and this hampers RA care.…Abstract Number: 1671 • ACR Convergence 2024
Are Patient-reported Outcomes for Dactylitis, Uveitis, Psoriatic Skin and Nail Disease Valid in Patients with Psoriatic Arthritis?
Background/Purpose: In routine care, Danish patients with psoriatic arthritis (PsA) are monitored in DANBIO, a nationwide clinical registry1. Patients enter patient-reported outcomes (PROs) online before…Abstract Number: 2157 • ACR Convergence 2024
Dimensionality of Inflammatory Back Pain Criteria in the US Population
Background/Purpose: The evaluation of axial spondyloarthritis relies on capturing various inflammatory back pain (IBP) features, represented in IBP criteria. This study examines the dimensionality of…Abstract Number: 2380 • ACR Convergence 2024
Characterizing SLE Patients into Type 1 and Type 2 Disease States: Insights from a Single Lupus Cohort
Background/Purpose: It has been proposed that SLE may be divided into Type 1 and Type 2 states. Type 1 manifestations are well captured in disease…Abstract Number: 0355 • ACR Convergence 2024
Improvements in Patient-Reported Outcomes After Treatment with SEL-212 in Adults with Refractory Gout: Results from Two Randomized Phase 3 Trials
Background/Purpose: Patients (pts) with gout have impaired health-related quality of life (HRQoL) relating to acute or chronic inflammation from elevated serum uric acid (sUA) levels.…Abstract Number: 0586 • ACR Convergence 2024
Real World Effectiveness of Upadacitinib in Patients with Psoriatic Arthritis Previously Treated with TNF Inhibitors: Data from the OM1 Registry
Background/Purpose: Upadacitinib (UPA), an oral JAK inhibitor, has demonstrated efficacy for the treatment of PsA in randomized controlled trials of patients with inadequate response or…Abstract Number: 0795 • ACR Convergence 2024
Prevalence of Post-exertional Malaise (PEM) in Adults with Rheumatic Diseases and Relationship with COVID19 Infection
Background/Purpose: Chronic fatigue is the dominant symptom in patients with Long COVID and Myalgic encephalomyelitis/Chronic fatigue syndrome (ME/CFS) as well as an important and prevalent…Abstract Number: 1247 • ACR Convergence 2024
Pre- and Post-Diagnosis Comparison of the Patient Experience of Sjögren’s Syndrome (SS): A Linguistic Analysis of Global Social Media Conversations
Background/Purpose: Patients with Sjögren’s Syndrome (SS) often undergo a prolonged and complex path to diagnosis and experience symptom, disease and treatment burdens with multiple co-morbid…Abstract Number: 1339 • ACR Convergence 2024
When Medications Fail: A Mixed Methods Study Evaluating the Experience and Health-Related Quality of Life (HRQOL) of Adults with Rheumatoid Arthritis Non-Responsive to Treatment
Background/Purpose: RA treatment involves an iterative approach to identifying effective medications for patients. While response varies, there is little in-depth understanding of patients’ perspectives of…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 43
- Next Page »